STOCK TITAN

NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

NeuroMetrix, Inc. (Nasdaq: NURO) recently announced a publication on the effects of wearable transcutaneous electrical nerve stimulation for fibromyalgia in the Journal of Pain Research. This study involved 119 subjects over a 3-month period, comparing active and sham treatments using the Quell device. Importantly, the Quell device's use for fibromyalgia remains investigational and has not received FDA approval. Fibromyalgia affects 2-6% of the U.S. population, highlighting the need for effective non-pharmacological treatments. NeuroMetrix focuses on non-invasive medical devices for pain and neurological disorders.

Positive
  • Publication in the Journal of Pain Research enhances credibility of Quell device.
  • Addresses a significant unmet need in fibromyalgia treatment.
Negative
  • Quell's use for fibromyalgia is still investigational and not FDA approved.

WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research. The article is available online at the journal website.

The article reports an intention-to-treat analysis of a double-blind, randomized, sham-controlled trial that compared 3-months of at-home treatment with a standard (active) or low dose (sham) Quell device in 119 subjects with fibromyalgia.

Note: The use of Quell for fibromyalgia is investigational and has not been cleared or approved by the U.S. Food and Drug Administration (FDA).

About Fibromyalgia

Fibromyalgia is a common form of chronic pain that is also accompanied by fatigue, sleep, cognitive and mood disturbances. It affects an estimated 2 to 6 percent of the U.S. population (5 to 15 million people) and is most often diagnosed between the ages of 30 and 50. The cause of fibromyalgia remains unclear, but scientific studies point to abnormalities in the way the brain processes normal sensations and pain. Although several drugs are FDA approved for managing fibromyalgia pain, there is an unmet need for safe and effective non-pharmacological treatments.

About Quell

Quell is an advanced, non-invasive, nerve stimulation device that is covered by 18 U.S. utility patents. It is the only wearable neurostimulator that is enabled by a custom designed microchip that provides precise, high-power nerve stimulation in a form factor the size of a credit card. Quell utilizes position and motion sensing to automatically adjust stimulation for an optimal patient experience both day and night. The device supports Bluetooth® low energy (BLE) to communicate with the Quell app, which is available for iOS and Android mobile devices. Quell is currently indicated for symptomatic relief and management of chronic lower extremity (knee, foot and leg) pain. It is available over-the-counter for this use. Visit QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Quell® is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain. For more information, visit www.NeuroMetrix.com.

Source: NeuroMetrix, Inc.

Thomas T. Higgins
SVP and Chief Financial Officer
781-314-2761
neurometrix.ir@neurometrix.com


FAQ

What is the recent publication by NeuroMetrix about?

The recent publication discusses the effects of the Quell device on fibromyalgia in the Journal of Pain Research.

What is the sample size of the NeuroMetrix study on fibromyalgia?

The study involved 119 subjects.

Is the Quell device FDA approved for fibromyalgia treatment?

No, the use of the Quell device for fibromyalgia is investigational and not FDA approved.

What percentage of the U.S. population is affected by fibromyalgia?

Fibromyalgia affects an estimated 2 to 6 percent of the U.S. population.

What type of device is Quell?

Quell is a wearable neurostimulation device indicated for chronic pain management.

NeuroMetrix, Inc.

NASDAQ:NURO

NURO Rankings

NURO Latest News

NURO Stock Data

8.01M
1.59M
25.45%
3.01%
2.08%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
WALTHAM